Skip to main content

Precision Medicine via Diagnostic Enzyme Activity Testing

Project description

A novel assay will test an individual's rate of drug clearance to enable precise dosing

In 2018 alone, more than 100 new therapeutic drugs were approved in the EU and US. From over-the-counter treatments for headache to sophisticated targeted treatments requiring prescriptions, drugs must combine just the right synthesis of ingredients to combat what ails us. However, effective treatment relies equally on 'how much' as it does on 'what', and that varies from person to person based on a multitude of factors. One of the most important is how fast a drug is 'cleared' by the body. PreMeDosE is developing a nearly universal enzyme assay to test the activity level of the enzyme responsible for clearing most therapeutics. It will provide clinicians with critical information for truly personalised dosing.

Host institution

HELSINGIN YLIOPISTO
Net EU contribution
€ 150 000,00
Address
Yliopistonkatu 3
00014 Helsingin Yliopisto
Finland

See on map

Region
Manner-Suomi Helsinki-Uusimaa Helsinki-Uusimaa
Activity type
Higher or Secondary Education Establishments
Other funding
No data

Beneficiaries (1)

HELSINGIN YLIOPISTO
Finland
Net EU contribution
€ 150 000,00
Address
Yliopistonkatu 3
00014 Helsingin Yliopisto

See on map

Region
Manner-Suomi Helsinki-Uusimaa Helsinki-Uusimaa
Activity type
Higher or Secondary Education Establishments
Other funding
No data